TY - JOUR
T1 - The EGAPP initiative
T2 - Lessons learned
AU - Calonge, Ned
AU - Klein, Roger D.
AU - Berg, Alfred O.
AU - Berg, Jonathan S.
AU - Armstrong, Katrina
AU - Botkin, Jeffrey
AU - Campos-Outcalt, Doug
AU - Djulbegovic, Benjamin
AU - Fisher, Nancy L.
AU - Ganiats, Theodore G.
AU - Haddow, James E.
AU - Hayes, Maxine
AU - Janssens, A. Cecile J.W.
AU - Kaye, Celia
AU - Lyman, Donald O.
AU - Offit, Kenneth
AU - Pauker, Stephen G.
AU - Phillips, Kathryn A.
AU - Piper, Margaret
AU - Richards, Carolyn Sue
AU - Scott, Joan A.
AU - Strickland, Ora L.
AU - Teutsch, Steven
AU - Tunis, Sean R.
AU - Veenstra, David L.
AU - Williams, Marc S.
AU - Zallen, Doris T.
PY - 2014/3
Y1 - 2014/3
N2 - The Evaluation of Genomic Applications in Practice and Prevention Working Group was first convened in 2005 to develop and test evidence-based methods for the evaluation of genomic tests in transition from research to clinical and public health practice. Over the ensuing years, the Working Group has met 26 times, publishing eight recommendation statements, two methods papers, and one outcomes paper, as well as planning and serving as technical experts on numerous associated systematic reviews. Evaluation of Genomic Applications in Practice and Prevention methods have evolved to address implications of the proliferation of genome-wide association studies and are currently expanding to face challenges expected from clinical implementation of whole-genome sequencing tests. In this article, we review the work of the Evaluation of Genomic Applications in Practice and Prevention Working Group over the first 8 years of its existence with an emphasis on lessons learned throughout the process. It is hoped that in addition to the published methods of the Working Group, the lessons we have learned along the way will be informative to others who are producers and consumers of evidence-based guidelines in the field of genomic medicine.
AB - The Evaluation of Genomic Applications in Practice and Prevention Working Group was first convened in 2005 to develop and test evidence-based methods for the evaluation of genomic tests in transition from research to clinical and public health practice. Over the ensuing years, the Working Group has met 26 times, publishing eight recommendation statements, two methods papers, and one outcomes paper, as well as planning and serving as technical experts on numerous associated systematic reviews. Evaluation of Genomic Applications in Practice and Prevention methods have evolved to address implications of the proliferation of genome-wide association studies and are currently expanding to face challenges expected from clinical implementation of whole-genome sequencing tests. In this article, we review the work of the Evaluation of Genomic Applications in Practice and Prevention Working Group over the first 8 years of its existence with an emphasis on lessons learned throughout the process. It is hoped that in addition to the published methods of the Working Group, the lessons we have learned along the way will be informative to others who are producers and consumers of evidence-based guidelines in the field of genomic medicine.
KW - Evidence-based medicine
KW - Genetics
KW - Guideline development
KW - Public health genomics
KW - Systematic review methods
UR - http://www.scopus.com/inward/record.url?scp=84895813688&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84895813688&partnerID=8YFLogxK
U2 - 10.1038/gim.2013.110
DO - 10.1038/gim.2013.110
M3 - Review article
C2 - 23928914
AN - SCOPUS:84895813688
SN - 1098-3600
VL - 16
SP - 217
EP - 224
JO - Genetics in Medicine
JF - Genetics in Medicine
IS - 3
ER -